Suppression of NRF2-dependent cancer growth by a covalent allosteric molecular glue
Nilotpal Roy, Tine L Wyseure, I‐Chung Lo, Justine Lu, Christie L. Eissler, Steffen M. Bernard, Ilah Bok, Aaron Nathan Snead, Aulma R. Parker, U‐Ging Lo, Jason C. Green, Jordon M. Inloes, Sarah R. Jacinto, Brent M. Kuenzi, Marie Pariollaud, , Matthew P. Patricelli
This paper introduces VVD-065, a covalent NRF2 inhibitor that enhances NRF2 degradation and sensitizes tumors to therapy, supporting a Phase I clinical trial.
Cancer Discovery · Dec 19, 2025Peer-reviewedCancer Biology